Prudential Financial Inc. Purchases 190,660 Shares of AMAG Pharmaceuticals, Inc. (AMAG)

Prudential Financial Inc. grew its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 35.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 725,357 shares of the specialty pharmaceutical company’s stock after purchasing an additional 190,660 shares during the quarter. Prudential Financial Inc. owned approximately 2.06% of AMAG Pharmaceuticals worth $13,382,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Teachers Advisors LLC lifted its stake in shares of AMAG Pharmaceuticals by 3.6% in the first quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock worth $1,399,000 after acquiring an additional 2,164 shares during the period. Legal & General Group Plc lifted its stake in shares of AMAG Pharmaceuticals by 1.3% in the first quarter. Legal & General Group Plc now owns 61,371 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after acquiring an additional 770 shares during the period. Vanguard Group Inc. lifted its stake in shares of AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after acquiring an additional 176,832 shares during the period. Dimensional Fund Advisors LP lifted its stake in AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock valued at $23,129,000 after buying an additional 619,370 shares during the period. Finally, BlackRock Inc. lifted its stake in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock valued at $112,647,000 after buying an additional 4,988,054 shares during the period.

AMAG has been the topic of several recent analyst reports. Cowen reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Deutsche Bank restated a “hold” rating and set a $24.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Morgan Stanley started coverage on AMAG Pharmaceuticals in a report on Friday, September 8th. They set an “overweight” rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $24.00.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) traded down $0.40 on Wednesday, reaching $13.95. The company had a trading volume of 659,672 shares, compared to its average volume of 1,094,128. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals, Inc. has a twelve month low of $11.93 and a twelve month high of $36.83.

ILLEGAL ACTIVITY NOTICE: “Prudential Financial Inc. Purchases 190,660 Shares of AMAG Pharmaceuticals, Inc. (AMAG)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/prudential-financial-inc-has-13-38-million-stake-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply